- Home
- CTO vs OMER Comparison
CTO vs OMER Comparison
Compare CTO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- OMER
- Stock Information
- Founded
- CTO 1902
- OMER 1994
- Country
- CTO United States
- OMER United States
- Employees
- CTO N/A
- OMER N/A
- Industry
- CTO Real Estate Investment Trusts
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- OMER Health Care
- Exchange
- CTO Nasdaq
- OMER Nasdaq
- Market Cap
- CTO 589.6M
- OMER 188.1M
- IPO Year
- CTO N/A
- OMER 2009
- Fundamental
- Price
- CTO $17.69
- OMER $3.20
- Analyst Decision
- CTO Strong Buy
- OMER Strong Buy
- Analyst Count
- CTO 3
- OMER 5
- Target Price
- CTO $22.33
- OMER $18.00
- AVG Volume (30 Days)
- CTO 372.4K
- OMER 941.4K
- Earning Date
- CTO 07-29-2025
- OMER 08-06-2025
- Dividend Yield
- CTO 8.59%
- OMER N/A
- EPS Growth
- CTO N/A
- OMER N/A
- EPS
- CTO N/A
- OMER N/A
- Revenue
- CTO $132,203,000.00
- OMER N/A
- Revenue This Year
- CTO $20.11
- OMER N/A
- Revenue Next Year
- CTO $8.51
- OMER $468.75
- P/E Ratio
- CTO N/A
- OMER N/A
- Revenue Growth
- CTO 17.48
- OMER N/A
- 52 Week Low
- CTO $16.12
- OMER $2.95
- 52 Week High
- CTO $21.15
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- CTO 45.36
- OMER 41.04
- Support Level
- CTO $17.10
- OMER $2.95
- Resistance Level
- CTO $17.71
- OMER $3.25
- Average True Range (ATR)
- CTO 0.37
- OMER 0.23
- MACD
- CTO -0.05
- OMER 0.06
- Stochastic Oscillator
- CTO 53.80
- OMER 38.46
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.